(Total Views: 585)
Posted On: 08/29/2025 9:31:50 AM
Post# of 158215
700mg Leronlimab Placebo 700mg Open Label
Arm/Group Description
Two syringes, each containing 350mg of leronlimab in 2mL, allowed administration of the 700mg dose, subcutaneously.
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Two syringes each containing 2mL of normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.
Two syringes, each containing 350mg leronlimab administered once weekly for 2 weeks.
Overall Number of Participants Analyzed "Measure Type: Count of Participants | Unit of Measure: Participants
LL: Same as placebo in Mortality and Survival
700 mg LLPlacebo Open label
259 125 89
Mortality: *52 20.1% 27 21.6% 23 25.8%
Survival:* 207 79.9% 98 78.4% 66 74.2%
https://clinicaltrials.gov/study/NCT04347239?tab=results
Arm/Group Description
Two syringes, each containing 350mg of leronlimab in 2mL, allowed administration of the 700mg dose, subcutaneously.
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Two syringes each containing 2mL of normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.
Two syringes, each containing 350mg leronlimab administered once weekly for 2 weeks.
Overall Number of Participants Analyzed "Measure Type: Count of Participants | Unit of Measure: Participants
LL: Same as placebo in Mortality and Survival
700 mg LLPlacebo Open label
259 125 89
Mortality: *52 20.1% 27 21.6% 23 25.8%
Survival:* 207 79.9% 98 78.4% 66 74.2%
https://clinicaltrials.gov/study/NCT04347239?tab=results
(1)
(0)
